Shasqi Inc.
San Francisco, CA Doing business as Shasqi Inc.
- UEI
- ZDH5UZ2858G3
- CAGE
- 8NXH9
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 665 3rd St #250, San Francisco, CA 94107, USA
- Website
- shasqi.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry - abstract shasqi, INC. Is… | National Cancer Institute | $3,330,432 | |
| Antigen-targeted activation of TOPO1 inhibitors via click chemistry - abstract most drugs are administered… | National Cancer Institute | $1,999,929 | |
| Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry - abstract shasqi is developing a… | National Cancer Institute | $2,781,419 | |
| Assessing the safety and efficacy of SQ3370 in a phase 1B dose-expansion cohort at the recommended phase 2 dose in… | National Cancer Institute | $5,050,186 | |
| Immune biomarker assessment and manufacturing development for SQ3370-001, a first-in-human phase i dose-escalation… | National Cancer Institute | $5,190,060 |
About Shasqi Inc.
Shasqi Inc. is a Hispanic American-owned biotechnology company based in San Francisco, California, focusing on innovative drug delivery technologies in the oncology space. The company has developed a proprietary Click Activated Protodrugs (CAPAC) platform that aims to enhance therapeutic efficacy by enabling precise and localized drug activation, specifically targeting cancer treatments. This approach seeks to minimize systemic toxicity and adverse drug events by using bioorthogonal click chemistry to activate potent cytotoxic drugs exclusively at tumor sites.
Through federal grant awards from the National Cancer Institute (NCI), Shasqi Inc. has consistently received project grants to advance its cancer treatment research and development strategies. The company has secured multiple grants totaling over $3 million, focusing on innovative approaches to drug delivery and cancer treatment. These grants have supported research on specific projects such as CEACAM5-targeted activation of chemotherapeutics, antigen-targeted activation of topoisomerase I inhibitors, and antibody-guided localized activation of bioorthogonal protodrugs. The grants have enabled Shasqi to develop and test its lead product SQ3370, a novel drug designed to reduce systemic toxicity while maintaining antitumor efficacy, with a particular focus on soft tissue sarcoma treatments. The research has progressed through preclinical studies and early-stage clinical trials, demonstrating significant potential in tumor growth inhibition, immune activation, and prolonged survival with reduced side effects compared to conventional chemotherapy approaches.
Quick answers
What is Shasqi Inc.'s UEI?
Shasqi Inc.'s Unique Entity ID (UEI) in SAM.gov is ZDH5UZ2858G3.
What is Shasqi Inc.'s CAGE code?
Shasqi Inc.'s CAGE code is 8NXH9.
Where is Shasqi Inc. located?
Shasqi Inc.'s physical address in SAM.gov is 665 3rd St #250, San Francisco, CA 94107, USA.
Is Shasqi Inc. registered in SAM.gov?
Yes. Shasqi Inc.'s SAM.gov registration is active through December 12, 2026.
What is Shasqi Inc.'s most recent federal award?
Shasqi Inc.'s most recent federal grant award is CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry - abstract shasqi, INC. Is… (R44CA306491), from National Cancer Institute, on September 25, 2025.
On GovTribe
See Shasqi Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors